{
    "organizations": [],
    "uuid": "74fe75ee2d91ed6f71f6d990b13ffb8a5d617297",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-molecular-partners-promising-initi/brief-molecular-partners-promising-initial-safety-and-efficacy-data-from-phase-2-study-of-mp0250-idUSFWN1P301B",
    "ord_in_thread": 0,
    "title": "BRIEF-Molecular Partners: Promising Initial Safety And Efficacy Data From Phase 2 Study Of MP0250",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - MOLECULAR PARTNERS AG:\n* REPORTS PROMISING INITIAL SAFETY AND EFFICACY DATA FROM ITS ONGOING PHASE 2 STUDY OF MP0250 IN MULTIPLE MYELOMA\n* ADDITIONAL SAFETY AND EFFICACY DATA ARE EXPECTED BY END OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-08T14:04:00.000+02:00",
    "crawled": "2018-01-09T17:10:48.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "molecular",
        "partner",
        "ag",
        "report",
        "promising",
        "initial",
        "safety",
        "efficacy",
        "data",
        "ongoing",
        "phase",
        "study",
        "mp0250",
        "multiple",
        "myeloma",
        "additional",
        "safety",
        "efficacy",
        "data",
        "expected",
        "end",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}